Evidence map›Paper›PMID 41029719›Full record

ArticleJournal of biological engineering2025

Streamlined purification of ADDomer nanoparticles for scalable biomanufacturing.

Raquel Arinto-Garcia, Cláudia S Paiva, Emerson Bryan Dilla, Dirk E Martens, Justin Sargunas, Michael Betenbaugh, Dora Buzas, Georgia Balchin, Mafalda Moleirinho, Rute Castro and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Raquel Arinto-Garcia *IBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780- 901, Portugal.
Cláudia S Paiva *IBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780- 901, Portugal.
Emerson Bryan DillaWageningen University & Research, Droevendaalsesteeg 1, 6708PB, Wageningen, The Netherlands.
Dirk E MartensWageningen University & Research, Droevendaalsesteeg 1, 6708PB, Wageningen, The Netherlands.
Justin SargunasJohns Hopkins University, Baltimore, MD, 21218, USA.
Michael BetenbaughJohns Hopkins University, Baltimore, MD, 21218, USA.
Dora BuzasSchool of Biochemistry, Biomedical Sciences Building, University of Bristol, University Walk, Bristol, BS8 1TD, UK.
Georgia BalchinSchool of Biochemistry, Biomedical Sciences Building, University of Bristol, University Walk, Bristol, BS8 1TD, UK.
Mafalda MoleirinhoIBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780- 901, Portugal.
Rute CastroIBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780- 901, Portugal.
Cristina PeixotoIBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780- 901, Portugal.
Imre BergerSchool of Biochemistry, Biomedical Sciences Building, University of Bristol, University Walk, Bristol, BS8 1TD, UK.
Christiane SchaffitzelSchool of Biochemistry, Biomedical Sciences Building, University of Bristol, University Walk, Bristol, BS8 1TD, UK.
Paula M AlvesIBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780- 901, Portugal.
António RoldãoIBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780- 901, Portugal. aroldao@ibet.pt.

Funding

Fundação para a Ciência e a Tecnologia LA/P/0087/2020Horizon 2020 Framework Programme 899670iNOVA4Health Programme in Translational Medicine 04462
6 · The paper itself

Abstract

Current lab-scale purification methods for ADDomer are labour-intensive, time-consuming and poorly scalable. The intracellular nature of ADDomer production further complicates downstream processing, requiring robust, scalable solutions for cell lysis and clarification. In the present work we focus on developing a scalable, GMP-compliant process for ADDomer purification. The workflow combines tangential microfiltration (TMF) using a 0.4 μm hollow fiber for cell retention, chemical lysis with 0.06 % Deviron

Indexed as

Adenovirus-like particles (ADDomer)Baculovirus expression vector system (BEVS)Downstream process developmentInsect cells

Identifiers

PMID41029719
PMCPMC12487075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.